Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
[google_news title=”” keyword=”stem cell transplant” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Stem cell treatment halts MS for some patientson September 30, 2023 at 6:50 am
A new study is strengthening the evidence that stem cell transplants can be highly effective for some people with multiple sclerosis—sending the disease into remission for years, and sometimes ...
- Vera Clinic: Pioneers of Stem Cell Hair Transplant Turkeyon September 29, 2023 at 10:17 am
Hair loss is an issue that transcends borders and affects millions of people worldwide, irrespective of their age or gender. Its ramifications extend beyond the physical realm, often taking a toll on ...
- Baby with rare blood cancer finally finds stem cell match: ‘A real pinch me moment’on September 28, 2023 at 10:29 pm
A real pinch me moment’ - Francis’s mother says son ‘is fine in himself at the moment’ despite undergoing chemotherapy ...
- Brazil's diversity makes country a testing ground for a global stem cell biobank, scientists sayon September 28, 2023 at 8:00 am
A biobank for all, in which a person from any background could find a bone marrow donor for a stem cell transplant, is a major goal for stem cell science. While repositories of cell lines that could ...
- Stem Cell Therapy May Help Treat Multiple Sclerosison September 28, 2023 at 3:10 am
New research finds a stem cell treatment is effective and generally safe for treating relapsing-remitting multiple sclerosis.
- Fitness of Cells Used in Cell Transplants Improvedon September 28, 2023 at 2:13 am
Researchers found exposing cells to a small molecule drug improved their fitness during hematopoietic stem cell transplants, which could broaden access and improve outcomes for ex vivo gene therapy.
- Stem cell transplants may reverse disability for some MS patientson September 27, 2023 at 11:19 am
A new study is strengthening the evidence that stem cell transplants can be highly effective for some people with multiple sclerosis -- sending the disease into remission for years, and sometimes ...
- Aphexda Plus Filgrastim Boosts Stem Cell Mobilization in Patients With Myelomaon September 27, 2023 at 8:00 am
The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma.
- Multiple sclerosis: How stem cell therapy could become a treatment for MSon September 27, 2023 at 1:45 am
Researchers are looking into stem cell therapies as potential treatments for a variety of multiple sclerosis conditions. The findings are promising, but experts say there still is a lot of work to be ...
- Stem cell transplant refreshes brain cells to treat Alzheimer's in miceon September 26, 2023 at 7:37 pm
Scientists at Stanford Medicine have tested a new potential treatment for Alzheimer’s disease in mice. The therapy involves transplanting blood stem cells from healthy mice into those with the disease ...
via Google News and Bing News